A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis.

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Biogen
  • Most Recent Events

    • 19 Jun 2018 Results of subgroup analysis of ADVANCE/ATTAIN presented at the 4th Congress of the European Academy of Neurology
    • 27 Apr 2018 Results of a subgroup analysis from ADVANCE, ATTAIN, TEMSO and TOWER studies comparing the clinical outcomes of peginterferon beta-1a and teriflunomide in DMT niave RMS patients, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 28 Oct 2017 Results of a sub-group (newly diagnosed, treatment-naive patients) analysis evaluating the effect of peginterferon beta-1a on clinical and radiological disease activity presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top